The combination of treatments enhanced the apoptotic rate from 17% (afatinib alone) to 63% when combined with 20 μg/mL Sp-R-A, suggesting its potential as a co-therapeutic strategy for NSCLC. This evidence concerns the gene TFF2 and non-small cell lung carcinoma.